FDA's newly designated treatment INDs.
Young
F E
FE
Food and Drug Administration, Rockville, MD 20857.
Nightingale
S L
SL
D002985:Clinical Protocols; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000628:therapy*; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005965:Glucuronates / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage*; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D016030:Kidney Transplantation; D002955:Leucovorin / Q000008:administration & dosage; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016597:Trimetrexate / Q000031:analogs & derivatives*; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D005965:Glucuronates; D007106:Immune Sera; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D011799:Quinazolines; C045781:cytomegalovirus-specific hyperimmune globulin; C056321:trimetrexate glucuronate; D002955:Leucovorin; D016597:Trimetrexate